Madeleine M. Fletcher

Madeleine M. Fletcher

Auto-generated profile, based on publicly available information

Madeleine M. Fletcher

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Science
Verified
Journal Article
Closed access
JCJianjun Cao
Jianjun Cao
MBMatthew J. Belousoff
Matthew J. Belousoff
YLYi-Lynn Liang
Yi-Lynn Liang
RJRachel M. Johnson
Rachel M. Johnson
TJTracy Josephs
Tracy Josephs
PSPatrick M Sexton
Patrick M Sexton
Amylin receptors (AMYRs) are heterodimers of the calcitonin (CT) receptor (CTR) and one of three receptor activity–modifying proteins (RAMPs), AMY 1 R, AMY 2 R, and AMY 3 R. Selective AMYR agonists and dual AMYR/CTR agonists are being developed as obesity treatments; however, the molecular basis for peptide binding and selectivity is unknown. We determined the structure and dynamics of active AMYRs with amylin, AMY 1 R with salmon CT (sCT), AMY 2 R with sCT or human CT (hCT), and CTR with amylin, sCT, or hCT. The conformation of amylin-bound complexes was similar for all AMYRs, constrained by the RAMP, and an ordered midpeptide motif that we call the bypass motif. The CT-bound AMYR complexes were distinct, overlapping the CT-bound CTR complexes. Our findings indicate that activation of AMYRs by CT-based peptides is distinct from their activation by amylin-based peptides. This has important implications for the development of AMYR therapeutics.

16 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSarah Piper
Sarah Piper
GDGiuseppe Deganutti
Giuseppe Deganutti
JLJessica Lu
Jessica Lu
PZPeishen (Elva) Zhao
Peishen (Elva) Zhao
YLYi-Lynn Liang
Yi-Lynn Liang
DWDenise Wootten
Denise Wootten
The vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) receptors are key regulators of neurological processes. Despite recent structural data, a comprehensive understanding of peptide binding and selectivity among different subfamily receptors is lacking. Here, we determine structures of active, Gs-coupled, VIP-VPAC1R, PACAP27-VPAC1R, and PACAP27-PAC1R complexes. Cryo-EM structural analyses and molecular dynamics simulations (MDSs) reveal fewer stable interactions between VPAC1R and VIP than for PACAP27, more extensive dynamics of VIP interaction with extracellular loop 3, and receptor-dependent differences in interactions of conserved N-terminal peptide residues with the receptor core. MD of VIP modelled into PAC1R predicts more transient VIP-PAC1R interactions in the receptor core, compared to VIP-VPAC1R, which may underlie the selectivity of VIP for VPAC1R over PAC1R. Collectively, our work improves molecular understanding of peptide engagement with the PAC1R and VPAC1R that may benefit the development of novel selective agonists.

27 May 2025 in Biochemistry
Verified
Journal Article
Closed access
GMGrace Mennen
Grace Mennen
ZYZi Ying
Zi Ying
MFMadeleine M. Fletcher
Madeleine M. Fletcher
MRMuhammad Abdur Razzak
Muhammad Abdur Razzak
LHLaura Humphrys
Laura Humphrys
PZPeishen (Elva) Zhao
Peishen (Elva) Zhao

5 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BCBrian P. Cary
Brian P. Cary
EGElliot J. Gerrard
Elliot J. Gerrard
MBMatthew J. Belousoff
Matthew J. Belousoff
MFMadeleine M. Fletcher
Madeleine M. Fletcher
YJYan Jiang
Yan Jiang
PSPatrick M Sexton
Patrick M Sexton
The parathyroid hormone (PTH) 1 receptor (PTH1R) is a class B1 G protein-coupled receptor (GPCR) that critically regulates skeletal development and calcium homeostasis. Despite extensive study, the molecular underpinnings of PTH1R stimulation by its cognate hormones, as well as by therapeutic agents, remain unclear. Here, we describe cryo-EM structures of the PTH1R in complex with active fragments of the two hormones, PTH and parathyroid hormone related protein (PTHrP), the peptidic drug abaloparatide, as well as the engineered tool compounds, long-acting PTH (LA-PTH) and the truncated peptide, M-PTH(1-14). We found that the N-terminus of each agonist that is critical for activity, engages the transmembrane bundle in a topologically similar fashion, which reflects similarities in measures of Gαs activation. The full-length peptides bind the extracellular domain (ECD) using a shared interface but induce subtly different ECD orientations relative to the transmembrane domain (TMD). In the structure bound to M-PTH, an agonist which only binds the TMD, the ECD is completely unresolved, demonstrating that the ECD is highly dynamic when unconstrained by a peptide. High resolutions enabled identification of water molecules near the peptide and G protein binding sites, some of which are structurally conserved with other class B1 GPCRs. Our results shed light on the action of orthosteric agonists of the PTH1R and provide a foundation for structure based-drug design.